Selinexor with azacitidine for high-risk blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have high-risk myelodysplastic syndrome (MDS) or high-risk acute myeloid leukemia (AML).
- Your AML is hard to treat, has come back, or has minimal residual disease (MRD) before a transplant.
- You have chronic myelomonocytic leukemia (CMML) or your MDS or CMML has turned into AML.
- You are not pregnant and can use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
This trial tests a three-drug combination (selinisole, azacitidine, and venetoclax) for newly diagnosed high-risk blood cancers with a TP53 gene change. These drugs aim to target the cancer while skipping standard chemotherapy, possibly making treatment more effective and less harsh.
This study tests a combination of two drugs (azacitidine or ruxolitinib plus selinexor) for people with MDS/MPN overlap syndrome, a type of blood cancer. It aims to see if this treatment helps control symptoms and improve blood counts.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.